U.S. Markets closed

Jazz Pharmaceuticals Public Limited Company (JAZZ)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
151.11-0.94 (-0.62%)
At close: 4:00PM EDT
People also watch
ALXNBMRNREGNMDVNICPT
Interactive chart
Previous Close152.05
Open152.88
Bid103.07 x 100
Ask165.00 x 100
Day's Range150.95 - 155.00
52 Week Range95.80 - 163.75
Volume276,714
Avg. Volume525,685
Market Cap9.07B
Beta1.52
PE Ratio (TTM)22.83
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : May 29, 2017
    Capital Cube9 hours ago

    Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : May 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jazz Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • BioLineRx Makes Regulatory Submission for Trial of BL-8040
    Zacks6 days ago

    BioLineRx Makes Regulatory Submission for Trial of BL-8040

    BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

  • Capital Cube7 days ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : May 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)